Swedish Orphan Biovitrum AB: Business description, financial summary, 3yr and interim financials, key statistics/ratios and historical ratio analysis.
Provider: Reuters Investment Profile
NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
Swedish Orphan Biovitrum AB Proposes No FY 2012 Dividend; Issues FY 2013 Financial Guidance in Line with Analysts' Estimates
Swedish Orphan Biovitrum AB announced that its Board of Directors proposes paying no dividend for fiscal year 2012. This is unchanged from fiscal year 2011. The Company also announced that it expects fiscal year 2013 total revenues in the range of between SEK 2,000 million and SEK 2,200 million. It also expects fiscal year 2013 gross margin in the range of between 57% and 59%. According to I/B/E/S estimates, analysts on average are expecting the Company to report fiscal year 2013 revenue of SEK 2,008.29 million and fiscal year 2013 gross margin of 57.29%.
Latest Developments for Swedish Orphan Biovitrum publ AB
- Swedish Orphan Biovitrum publ AB and Biogen Idec Inc announce results of phase 3 study of recombinant factor IX and VIII Fc fusion protein candidates
- Swedish Orphan Biovitrum publ AB and Biogen Idec Inc announce results of phase 3 study with ALPROLIX
- Swedish Orphan Biovitrum publ AB Receives Approval for Kineret for Treatment of CAPS
- Swedish Orphan Biovitrum publ AB Maintains FY 2013 Revenue Guidance
Latest Key Developments in Pharmaceuticals
- Share this
- Digg this